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ABSTRACT
Objective High-sensitivity troponin (hs-Tn) assays need
to be applied appropriately to improve diagnosis and
patient outcomes in acute coronary syndromes (ACS).
Methods Experts from Asia Paciﬁc convened in 2015
to provide data-driven consensus-based, region-speciﬁc
recommendations and develop an algorithm for the
appropriate incorporation of this assay into the ACS
assessment and treatment pathway.
Results Nine recommendations were developed by the
expert panel: (1) troponin is the preferred cardiac
biomarker for diagnostic assessment of ACS and is
indicated for patients with symptoms of possible ACS;
(2) hs-Tn assays are recommended; (3) serial testing is
required for all patients; (4) testing should be performed
at presentation and 3 hours later; (5) gender-speciﬁc
cut-off values should be used for hs-Tn I assays; (6) hs-
Tn I level >10 times the upper limit of normal should be
considered to ‘rule in’ a diagnosis of ACS; (7) dynamic
change >50% in hs-Tn I level from presentation to 3-
hour retest identiﬁes patients at high risk for ACS; (8)
where only point-of-care testing is available, patients
with elevated readings should be considered at high risk,
while patients with low/undetectable readings should be
retested after 6 hours or sent for laboratory testing and
(9) regular education on the appropriate use of troponin
tests is essential.
Conclusions We propose an algorithm that will
potentially reduce delays in discharge by the accurate
‘rule out’ of non-ACS patients within 3 hours.
Appropriate research should be undertaken to ensure the
efﬁcacy and safety of the algorithm in clinical practice,
with the long-term goal of improvement of care of
patients with ACS in Asia Paciﬁc.
INTRODUCTION
The total burden of ischaemic heart disease in
Southeast Asia has increased by approximately
61.5% since 1990.1–3 Consequently, hospital emer-
gency departments (EDs) are seeing increasing
number of patients presenting with chest pain and
other signs of acute coronary syndromes (ACS).
The emergent nature of ACS renders it important
to rapidly and accurately diagnose and risk stratify
patients. The diagnostic algorithm of non-ST
segment elevation ACS involves the use of cardiac
biomarkers, such as troponin, alongside patient’s
history, symptoms, clinical signs, ECG parameters
and available imaging (eg, echocardiography) for
drawing sound clinical judgements.4 5
An Asia Paciﬁc expert meeting was convened in
Singapore on 21 November 2015 to discuss
regional practice in the current use of high-
sensitivity troponin (hs-Tn) assays, speciﬁcally, the
hs-Tn I assay and to develop an algorithm to appro-
priately use this assay in assessing and treating ACS.
This article describes the consensus in the use of
hs-Tn assays and provides recommendations
deemed suitable for this region.
Use of troponin assays in Asia Paciﬁc
Currently, there are limited data on the use of differ-
ent troponin assays throughout Asia Paciﬁc.
Discussion at the consensus meeting revealed that
most tertiary centres use troponin levels in ACS diag-
nosis, many of which commonly use hs-Tn assays for
either troponin T or I, while some still use contem-
porary standard assays. In some resource-limited set-
tings, CK-MB levels were still used. In suburban or
rural areas of Australia, Thailand and Malaysia,
where there is limited access to 24-hour laboratory
services, point-of-care (POC) assays were used.
Therefore, we have also included a statement regard-
ing POC assays.
Troponin assays
A range of troponin assays are currently available
for quantiﬁcation of troponin Tor I, most of which
are described as hs assays while some may not fulﬁl
the standard criteria. These criteria include: (1)
having a coefﬁcient of variation (CV) of ≤10% at
the 99th percentile of the reference population and
(2) being able to measure concentrations below the
99th percentile and above the assay’s limit of detec-
tion in at least 50% (and ideally >95%) of healthy
individuals.6
The 99th percentile is the concentration below
which troponin levels lie for 99% of the healthy
population (the upper reference limit). The 10%
CV is the troponin concentration at which the ana-
lytic concentration of troponin is 10% and gener-
ally lies at the lower end of the acute myocardial
infarction (MI) curve (ﬁgure 1).7 The ratio of the
10% CV to the 99th percentile provides an esti-
mate of precision—the smaller the ratio, the higher
the precision.7 The 99th percentile and 10% CV
differ between assays (table 1).
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As shown in ﬁgure 1, the distribution of hs-Tn levels is
non-Gaussian and positively skewed.9–11 Moreover, the distribu-
tion of cardiac troponin levels is affected by gender and renal
function, and potentially by age and ethnicity, leading to differ-
ent 99th percentile and 10% CV in different populations.8 12–17
Gender differences may be particularly important clinically.
Studies comparing cardiac troponin I levels measured by
Abbott’s high-sensitivity ARCHITECT STAT assay showed that
the 99th percentile is consistently lower in women than men
(table 2).8 9 15–19 Thus, if the 99th percentile for the overall
population is used, a number of women with ACS may not be
identiﬁed. In contrast, using gender-speciﬁc thresholds may
double the number of women who are correctly diagnosed with
MI, without affecting the number of diagnosed men.20
METHODS
The expert panel was selected from a pool of practicing cardiolo-
gists, emergency physicians and chemical pathologists from Asia
Paciﬁc countries (Singapore, Malaysia, Philippines, Vietnam,
Indonesia, Thailand, Hong Kong and Australia). The main criter-
ion for selection was experience in the clinical or research use of
troponin assays. The panel discussed the current literature on
hs-Tn testing and developed an algorithm (ﬁgure 2) and consen-
sus recommendations for the appropriate use of these tests in
Asia Paciﬁc based on their understanding of the literature and
individual clinical experience. The wording of each key consen-
sus statement and algorithm was determined through discussion
until unanimously agreed. Subsequently, the supporting evidence
for the algorithm and for each statement was searched via
PubMed, and the wording developed. This was circulated to the
entire group, incorporating all feedback and recirculated for
unanimous agreement.
RESULTS
Consensus statements
Troponin is the preferred cardiac biomarker for diagnosing ACS
and is indicated for patients with possible ACS
Supporting evidence
Current international guidelines advocate the use of troponin,
preferably high-sensitivity assays, during the diagnostic workup
of suspected patients with ACS and without ST-segment eleva-
tion,4 21–24 and troponin is the preferred biomarker in the
Figure 1 Distribution of
high-sensitivity (hs) troponin levels in a
healthy population and patients with
acute myocardial infarction (AMI), with
an indication of the concentration
deﬁned by the 99th percentile and the
upper 10% coefﬁcient of variation (CV)
of the 99th percentile.
Table 1 Analytical characteristics of high-sensitivity cardiac troponin assays6 8 9
Cardiac troponin concentrations (ng/L) at:
Assay (manufacturer) Lower limit of detection 99th percentile (CV†) 10% CV Measurable values* (% subjects)
Troponin T
Elecsys (Roche) 5.0 14 (8%) 13 NA
Troponin I
Access (Beckman) 2–3 8.6 (10%) 8.6 80
ARCHITECT (Abbott)‡ 1.5 25.6 (<5%) 6.0 92.3
Erenna (Singulex) 0.09 10.1 (9%) 0.88 100
MTP (Nanosphere) 0.2 2.8 (9.5%) 0.5 NA
Vista (Siemens) 0.5 9 (5%) 3 86
Adapted from Apple et al.6 Reproduced with permission from the American Association for Clinical Chemistry.
*Proportion of subjects with levels above the lower limit of detection.
†CV at 99th percentile.
‡Taken from Aw et al.9
CV, coefficient of variation; MTP, microtiter plate.
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European Society of Cardiology/American College of
Cardiology Foundation/American Heart Association/World
Heart Federation Task Force for the Universal Deﬁnition of
Myocardial Infarction.25 Troponin is more sensitive and speciﬁc
to myocardial injury than creatine kinase (CK), CK-muscle and
brain (MB) or myoglobin.24–27 CK-MB should only be used at
Asia Paciﬁc centres where troponin testing is unavailable.
The hs-Tn assays should be used in clinical care, with ng/L as the
standard unit of measurement
Supporting evidence
The recommended unit of measurement for troponin I or T
level reporting in Asia Paciﬁc is ng/L, consistent with the
recommendations of the International Federation of Clinical
Chemistry and Laboratory Medicine Task Force on Clinical
Applications of Cardiac Biomarkers.6
Serial testing is required for all patients requiring troponin testing
Supporting evidence
Troponin levels evolve over the course of ACS,28 reﬂecting the
extent of myocardial damage.24 International guidelines now
recommend that more than one hs-Tn test is taken during the
assessment and treatment of patients with suspected ACS.4 22 24
Serial measurements allow physicians to assess the change in
hs-Tn levels, which (when considered together with the baseline
level) increases the negative predictive value of the test.29 30
Table 2 Comparison of 99th percentile values in men, women and mixed gender populations (general, non-cardiac or healthy individuals) in
different studies using the Abbott ARCHITECT STAT high-sensitivity troponin I package
99th percentile (ng/L)
Source Country Age (years) Specimen type n Female Male Overall
Package insert USA 18–75 All 4593 15.6 34.2 26.2
EDTA 1531 16.7 35.1 27.8
Serum 1529 14.7 32.1 22.3
Lithium heparin 1531 14.3 34.5 26.9
Apple et al 20128 USA 18–64 Lithium heparin 524 15 36 23
Koerbin et al 201218 Australia 20–84 Serum 497 11.1 14.0 13.6
Aw et al 20139 Singapore 35–65 Serum 1120 17.9 32.7 25.6
Krintus et al 201415 Europe* 18–91 Serum 1769 11.4 27 19.3
Zeller et al 201419 Scotland 40–59 Serum 12 650 18.1 31.7 23.9
Collinson et al 201517 England 45–89 Serum 599 9.9 28.5 21.0
Zeller et al 201516 Germany 35–75 Serum 4138 19.9 33.1 27.0
*Nine laboratories in Austria, Belgium, Denmark, France, Germany, Italy, Norway, Poland and Spain.
Figure 2 Consensus-based algorithm for the recommended use and interpretation of high-sensitivity troponin I (hs-Tn I) levels in Asia Paciﬁc. ACS,
acute coronary syndromes; ULN, upper limit of normal.
Tan JWC, et al. Heart Asia 2017;9:81–87. doi:10.1136/heartasia-2016-010818 83
Clinical practice
group.bmj.com on September 18, 2017 - Published by http://heartasia.bmj.com/Downloaded from 
Data with hs-Tn I assays show that a single baseline hs-Tn test
could accurately identify 88%–95% of patients with AMI
(depending on presentation time after chest pain onset), but
serial measurements increased the detection rate of AMI to
100%.31 Serial testing improves the diagnostic accuracy of hs-Tn
I and hs-Tn T levels.32 Stable hs-Tn levels during serial testing
are likely to indicate chronic myocardial damage,33 such as
heart failure.34
For hs-Tn, testing is suggested at the time of presentation
(0 hour) and 3 hours later
Supporting evidence
The initial hs-Tn test should be conducted as soon as possible
after presentation. Although the optimal timing of the second
hs-Tn measurement has not been established, the European
guidelines recommend retesting at 1 or 3 hours after presenta-
tion.24 However, the Asia Paciﬁc expert panel recommends
retesting at 3 hours for the following reasons:
▸ Retesting at 3 hours is recommended in the Third Universal
Deﬁnition of MI.25
▸ Using both the baseline level and a change in hs-Tn measured
after 1 or 2 hours provides a small but non-signiﬁcant
improvement in diagnostic performance relative to that of a
single baseline measure.35 Using both the baseline level and a
change in hs-Tn measured at 3 hours produces a marked
improvement in the positive predictive value (PPV) of the
hs-Tn I assay.28
▸ Clinical experience in Asia suggests that it may be impractical
to retest at 1 hour because it is often difﬁcult to get the
second sample so soon after presentation due to logistical
and personnel constraints. Most laboratories within Asia
Paciﬁc do not have the turnaround speed required to make
the 1-hour draw meaningful.
Gender-speciﬁc cut-offs should be considered for the Abbott
hs-Tn I assay (99th percentile: 16 ng/L for women; 34 ng/L
for men)
Supporting evidence
The clinical spectrum of ACS differs between men and women.
Women tend to develop ACS at an older age than men and are
more likely to have comorbidities, such as diabetes, hyperten-
sion, renal dysfunction or overweight/obesity.36–41 Coronary
artery disease is more likely to go undetected in women than
men, because their coronary atheroma burden is lower and they
are more likely to have non-obstructive disease on angiog-
raphy.36 40 42 43 The Valsartan in Acute Myocardial Infarction
Trial indicated that women and men had a similar age-adjusted
and risk factor-adjusted mortality rate after ACS, but the inci-
dence of composite cardiovascular events was higher in women
because of greater rates of hospitalisation.44
In addition, the symptoms of ACS differ between genders—
women are less likely to experience chest pain,45 46 and are more
likely to experience shortness of breath or nausea.46 47 This
could lead to delays in diagnosis48 and more conservative treat-
ment of women with non-ST-segment elevation ACS,49 which
may result in unsatisfactory outcomes. Studies in Singapore38
and Korea39 suggest that women in these countries have higher
mortality rate after ACS than men. Within Asia Paciﬁc, social
support for women may also be poorer compared with men.
These gender differences highlight the importance of accur-
ately diagnosing ACS in women. As described earlier, using
gender-speciﬁc 99th percentiles signiﬁcantly increases the
number of women who are accurately diagnosed with ACS,
without affecting the number of men diagnosed.20 Therefore,
the Asia Paciﬁc consensus group supports the use of gender-
speciﬁc thresholds in the interpretation of hs-Tn I levels, such as
that in the Abbott ARCHITECT STAT assay product insert,
which recommends thresholds of 16 ng/L in women and 34 ng/
L in men.
For ruling in AMI, the cut-off for a highly abnormal reading is 10
times the upper limit of normal
Supporting evidence
With the early (contemporary) cardiac troponin tests, any
detectable cardiac troponin could be assumed to result from
acute myocardial injury, making it simple to ‘rule in’ patients
with elevated levels as having ACS.34 However, high-sensitivity
assays are now capable of detecting much lower levels of circu-
lating troponin that may be indicative of more subtle or transi-
ent myocardial injury, not necessarily ACS.34 Therefore, to ‘rule
in’ a diagnosis of ACS, a clear elevation in hs-Tn is required.
The Asia Paciﬁc consensus group recommends that only hs-Tn
I levels of more than 10 times the upper limit of normal (ULN)
should be considered as markedly elevated. Current European
guidelines use a ‘rule-in’ level of 52 ng/L for hs-Tn T (Roche
assay) and for hs-Tn I (Abbott assay).24 These levels are approxi-
mately four and two times the ULN for hs-Tn T (based on a
99th percentile of 14 ng/L) and hs-Tn I (based on a 99th per-
centile of 26 ng/L), respectively. Early studies with hs-Tn T
showed that using a threshold of ﬁve times the ULN still only
had a PPV of 84%.50 Therefore, the Asia Paciﬁc consensus
group recommended a more stringent criterion, which has a
higher PPV. Patients with this magnitude of hs-Tn I elevation
can be considered as having a high diagnostic likelihood of ACS
and managed accordingly, but this does not preclude them from
a 3-hour retest to conﬁrm the diagnosis.
However, it must be emphasised that the diagnosis of ACS
should not be based merely on biomarker elevation. Rather, an
integrated approach should be taken, considering the presence
of factors associated with ACS, such as a patient history with
multiple CV risk factors, ischaemic ECG changes and echocar-
diographic wall-motion abnormalities.
For patients with hs-Tn I levels >99th percentile, a dynamic
change of >50% at the 3-hour retest classiﬁes them as high-risk
AMI. Patients with levels >99th percentile at baseline and a
dynamic change of <50% at 3 hours should be assessed for
alternate causes of elevated troponin
Supporting evidence
This recommendation is based on a careful analysis of the diag-
nostic performance of hs-Tn I levels using serial measurements
(at admission, 3 and 6 hours) in 1818 patients with suspected
ACS.28 The diagnostic performance parameters derived from
this analysis are shown in table 3.28 This study demonstrated
that the PPV of hs-Tn I is maximised when there is a >50%
change in the level between the admission test and the 3-hour
retest.28 A <50% change suggests that hs-Tn I levels remain
within a relatively stable range, likely indicating chronic
myocardial damage,34 which prompts for a reassessment of the
diagnosis.
Use of POC testing may be required in some suburban or rural
regions due to logistical limitations
A. If the reading is elevated, the patient may be classiﬁed as
high-risk disposition.
B. If the reading is normal or undetectable, repeat testing at 6
hours or send patient for formal lab testing: DO NOT
RULE OUTAMI.
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Supporting evidence
Wherever possible, the Asia Paciﬁc consensus group recom-
mends the use of laboratory assays for the determination of
hs-Tn levels. However, it is reasonable to use POC troponin
tests in some centres like rural hospitals, which may have
limited access to the required laboratory services.
POC troponin tests are less sensitive than hs-Tn laboratory
assays,51 52 with PPV only around 50%.52 Therefore, any
patient with an elevated troponin level on POC testing should
be considered as being at high risk of having ACS. These
patients should undergo further assessment according to the
algorithm outlined in ﬁgure 2. Any subsequent tests to assess
change should be undertaken using the same POC assay, as
there is considerable variability between assays.53
As POC troponin testing systems have good speciﬁcity but
low sensitivity, a result that is low or undetectable does not pre-
clude the possibility of ACS.54 It is recommended that a sample
is sent to the laboratory for hs-Tn evaluation. If this is impos-
sible, the POC troponin test should be repeated at 6 hours to
assess changes.
All personnel ordering troponin tests should be regularly educated
about the optimal use and interpretation of the result, based on
the assays used at respective centre
Supporting evidence
Modern hs-Tn assays provide an opportunity to improve ACS
diagnosis and patient outcomes, but, like any clinical tool, these
need to be applied appropriately for optimum beneﬁts. Data
showed that the introduction of these tests at a UK hospital was
suboptimal, with problems including inappropriate requests,55
incomplete information in the laboratory request56 and long
turnaround times for results.56 The Asia Paciﬁc consensus group
recommends regular education of personnel on the appropriate
use of troponin tests in clinical practice, including:
▸ The analytical characteristics of the test used at that hospital/
medical centre
▸ The need for serial testing in all patients
▸ The interpretation of the results in relation to the 99th per-
centile for that particular assay, including gender differences,
the units used, changes over time versus stable levels
▸ The integration of hs-Tn results into the diagnostic algo-
rithm, alongside other information from the patient’s history,
clinical signs, ECG and imaging results
▸ Caution in interpretation in presence of comorbidities. For
example, published data suggest that renal insufﬁciency may
inﬂuence the cut-off levels of certain hs-Tn assays.57
Education should be repeated at regular intervals or when
there is a change in assay or personnel, which include ED physi-
cians and nurses, cardiologists and medical students. When a
new laboratory assay for hs-Tn is being introduced, the educa-
tion should precede the assay’s introduction.
CONCLUSIONS
Given the increasing heart disease burden in this region, it is
important to optimise the diagnosis and treatment of patients
with ACS. This includes the appropriate use of hs-Tn levels for
diagnostic purposes, with the aim of preventing errors and
improving the standard of care. We proposed an algorithm that
will potentially reduce delays in discharge by the accurate ‘rule
out’ of patients without ACS within 3 hours, though it must be
considered in the full context of the management of suspected
ACS, which consists of a classical history in an individual with
multiple CV risk factors, ischaemic ECG changes and echocar-
diographic wall-motion abnormalities. This algorithm is merely
for the interpretation of hs-Tn I levels; it is not a complete diag-
nostic algorithm and therefore should be used in conjunction
with other clinical ﬁndings. We recommend that regular educa-
tion and appropriate research be undertaken to ensure the efﬁ-
cacy and safety of the algorithm in clinical practice, with the
long-term goal of improving care of patients with ACS regionally.
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Table 3 Diagnostic performance of the high-sensitivity troponin I (hs-Tn I) assay28
Performance parameter (95% CI)
Patient population Sensitivity Specificity PPV NPV
>99th percentile on admission (n=1260) 82.3 (77.3 to 86.5) 92.1 (90.3 to 93.7) 75.1 (69.9 to 79.8) 94.7 (93.1 to 96.1)
>99th percentile at 3 hours (n=1260) 98.2 (95.9 to 99.4) 90.4 (88.4 to 92.2) 74.7 (69.9 to 79.0) 99.4 (98.7 to 99.8)
>99th percentile on admission and hs-Tn I change 0–3 hours (n=1260) 50.0 (44.0 to 56.0) 99.1 (98.3 to 99.6) 94.0 (88.9 to 97.2) 87.3 (85.2 to 89.2)
Hs-Tn I change 0–3 hours and hs-Tn I >99th percentile at 3 hours in patients with
hs-Tn I <99th percentile on admission (n=951)
92.0 (80.8 to 97.8) 97.9 (96.7 to 98.7) 70.8 (58.2 to 81.4) 99.5 (98.8 to 99.9)
NPV, negative predictive value; PPV, positive predictive value.
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